



We're **breaking** the pattern.

At Fractyl Health (Nasdaq: \$GUTS), **we aim to free humanity from obesity and type 2 diabetes (T2D)** by breaking the pattern of drug dependence with innovative, root-cause solutions.

Chronic metabolic diseases are having devastating impacts on human health, society, and the economy.

Obesity and T2D have reached epidemic levels—with obesity rates doubling since 1990¹. If left unchecked, nearly 260 million Americans could be overweight or obese by 2050². Globally, these conditions contribute to \$3 trillion in costs annually, a figure projected to escalate to \$18 trillion by 2060³.

Fractyl seeks to address the global unmet need for sustainable solutions

Greater than 50% of patients discontinue GLP-1 drugs in less than 1 year⁴. Furthermore, weight and metabolic rebound occur rapidly upon discontinuation⁵. While currently approved drugs, as well as drugs in late-stage development may allow for weight loss, they do not solve the largest issue in obesity today—**durable weight maintenance**.

¹<https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>

²[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(24\)01548-4/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01548-4/fulltext)

³Okunogbe et al., "Economic Impacts of Overweight and Obesity." 2nd Edition with Estimates for 161 Countries. World Obesity Federation, 2022.

⁴Blue Health Intelligence, Issue Brief May 2024, Blue Cross Blue Shield

⁵Wilding JPH, Diabetes Obes Metab.2022;24:1553–1564



Fractyl is developing therapies designed to provide a durable metabolic reset—transforming outcomes beyond traditional drugs and incremental solutions.

Revita®: An outpatient endoscopic procedure.

Revita® resurfaces the lining of the duodenum, the hunger center of the gut. This procedure is designed to reset the body's metabolic setpoint, potentially leading to sustained weight maintenance after weight loss.

Rejuva®: A one-and-done gene therapy platform.

Rejuva® is designed to target the pancreas to potentially enable long-term remission of obesity and T2D. This therapy aims to restore the body's natural ability to regulate blood sugar and appetite, offering a durable solution beyond traditional drug treatments.

We trust our GUTS.

Our strategy centers on patient outcomes and driving innovative research. Revita is currently undergoing a pivotal study to evaluate its effects on weight loss, while Rejuva is on track to initiate FIH studies.

Revita is advancing through a pivotal clinical study*.


REMAIN-1 is a pivotal clinical study evaluating the effectiveness of Revita in patients with clinical obesity. This study compares Revita to a placebo treatment to assess its potential for maintaining weight loss after discontinuing a GLP-1 drug. REMAIN-1 aims to demonstrate Revita's ability to deliver lasting metabolic benefits and sustainable weight loss, offering a promising alternative to chronic drug therapies. REVEAL-1 is the open-label cohort of the REMAIN-1 study.

Rejuva is in preclinical development*.

Rejuva is designed to deliver lasting, disease-modifying benefits that could transform the treatment of metabolic diseases. Fractyl plans to submit the first Clinical Trial Application (CTA) module for RJVA-001 in T2D to regulators in the first half of 2025, and if the CTA is authorized, expects to report preliminary data in 2026. RJVA-002 was recently nominated as a candidate for obesity.

* The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use

*Revita is for investigational use only in the United States. Revita has a CE mark in the EU/UK.



Connect with us



fractyl.com